Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel + carboplatin + durvalumab with or without oleclumab in first-line metastatic or locally recurrent inoperable triple-negative breast cancer
2024-511850-34-00Phase 2Authorised
- Sponsor
- Institut Jules Bordet
- Start
- Jun 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Paclitaxel + carboplatin + durvalumab with Paclitaxel + carboplatin + durvalumab + oleclumab (2 arms). Primary endpoints: Safety and tolerability and Clinical benefit. Planned start Jun 2024; status: authorised.
02
Drugs
durvalumaboleclumabpaclitaxelcarboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2024-511850-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511850-34-00.